Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

RACHEL M SCHACHT

Allopathic & Osteopathic Physicians Dermatology

NPI
1912359480
CMS profile
1392591
Location
TUCSON, AZ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$1,149.57

64 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $973.18 61
Education $176.39 3

By paying entity

PY2024 · entire year · sorted by reported total

Page 2 of 2; records 51–64 of 64 matching records. This page contains 14 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

RACHEL M SCHACHT

NPI 1912359480 · CMS profile ID 1392591

Allopathic & Osteopathic Physicians / Dermatology

TUCSON, AZ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–64 of 64 matching records. This page contains 14 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1912359480?year=2024&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
RACHEL M SCHACHT, NPI 1912359480, CMS profile ID 1392591. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–64 of 64 matching records. This page contains 14 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1912359480?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). RACHEL M SCHACHT, NPI 1912359480, CMS profile ID 1392591. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–64 of 64 matching records. This page contains 14 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1912359480?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
RACHEL M SCHACHT, NPI 1912359480, CMS profile ID 1392591, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–64 of 64 matching records. This page contains 14 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1912359480?year=2024&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

64 matching records · $1,149.57 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 64 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–64 of 64.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ABBVIE INC. $8.0503/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106029440 CMS
Janssen Biotech, Inc. $6.9003/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078283779 CMS
Janssen Biotech, Inc. $16.9103/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078284677 CMS
UCB, Inc. $23.0303/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143323728 CMS
LEO Pharma Inc. $21.8002/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152650013 CMS
Janssen Biotech, Inc. $8.0402/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078283951 CMS
Janssen Biotech, Inc. $7.9902/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078284763 CMS
Regeneron Healthcare Solutions, Inc. $5.8502/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114158875 CMS
Regeneron Healthcare Solutions, Inc. $25.5502/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114158870 CMS
Janssen Biotech, Inc. $12.8102/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078283813 CMS
Janssen Biotech, Inc. $6.5501/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078284567 CMS
Amgen Inc. $19.5901/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117676713 CMS
Regeneron Healthcare Solutions, Inc. $26.2201/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114158866 CMS
Janssen Biotech, Inc. $21.5101/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078284319 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $261.32 5
PY2020 $105.09 6
PY2021 $663.10 24
PY2022 $1,146.61 51
PY2023 $1,014.13 62
PY2024 $1,149.57 64
PY2025 $291.50 3

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $157,884.94 29

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

29 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,100.00 12/03/2025 Non-covered Recipient Entity
NOBLE CLINICAL RESEARCH LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223289154
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $322.92 12/01/2025 Non-covered Recipient Entity
NOBLE CLINICAL RESEARCH LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223288875
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $912.53 12/01/2025 Non-covered Recipient Entity
NOBLE CLINICAL RESEARCH LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223288991
Principal investigator 1 ModernaTX, Inc. $11,483.91 11/21/2025 Non-covered Recipient Entity
NOBLE CLINICAL RESEARCH LLC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252989892
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,500.00 11/19/2025 Non-covered Recipient Entity
NOBLE CLINICAL RESEARCH LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223288495
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,000.00 11/19/2025 Non-covered Recipient Entity
NOBLE CLINICAL RESEARCH LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223288497
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $600.00 11/19/2025 Non-covered Recipient Entity
NOBLE CLINICAL RESEARCH LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223288499
Principal investigator 1 ModernaTX, Inc. $6,105.37 10/22/2025 Non-covered Recipient Entity
NOBLE CLINICAL RESEARCH LLC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252989904
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $44.16 10/22/2025 Non-covered Recipient Entity
NOBLE CLINICAL RESEARCH LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223287185
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,200.00 09/26/2025 Non-covered Recipient Entity
NOBLE CLINICAL RESEARCH LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223285905
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,644.58 09/26/2025 Non-covered Recipient Entity
NOBLE CLINICAL RESEARCH LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223285971
Principal investigator 1 ModernaTX, Inc. $8,240.13 09/19/2025 Non-covered Recipient Entity
NOBLE CLINICAL RESEARCH LLC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252989900
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,574.74 09/02/2025 Non-covered Recipient Entity
NOBLE CLINICAL RESEARCH LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223284775
Principal investigator 1 ModernaTX, Inc. $9,640.24 08/20/2025 Non-covered Recipient Entity
NOBLE CLINICAL RESEARCH LLC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252989894
Principal investigator 1 ModernaTX, Inc. $1,136.70 07/25/2025 Non-covered Recipient Entity
NOBLE CLINICAL RESEARCH LLC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252989914
Principal investigator 1 ModernaTX, Inc. $7,186.32 07/18/2025 Non-covered Recipient Entity
NOBLE CLINICAL RESEARCH LLC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252989908
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $11,143.17 07/02/2025 Non-covered Recipient Entity
NOBLE CLINICAL RESEARCH LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223282210
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $43.13 06/20/2025 Non-covered Recipient Entity
NOBLE CLINICAL RESEARCH LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223281726
Principal investigator 1 ModernaTX, Inc. $13,154.81 06/18/2025 Non-covered Recipient Entity
NOBLE CLINICAL RESEARCH LLC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252989896
Principal investigator 1 ModernaTX, Inc. $992.25 06/06/2025 Non-covered Recipient Entity
NOBLE CLINICAL RESEARCH LLC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252989912
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,427.08 06/06/2025 Non-covered Recipient Entity
NOBLE CLINICAL RESEARCH LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223280914
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $103.50 05/28/2025 Non-covered Recipient Entity
NOBLE CLINICAL RESEARCH LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223280498
Principal investigator 1 ModernaTX, Inc. $4,964.22 05/21/2025 Non-covered Recipient Entity
NOBLE CLINICAL RESEARCH LLC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252989916
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $12,690.16 05/07/2025 Non-covered Recipient Entity
NOBLE CLINICAL RESEARCH LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223279146
Principal investigator 1 ModernaTX, Inc. $11,450.16 05/02/2025 Non-covered Recipient Entity
NOBLE CLINICAL RESEARCH LLC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252989906
Principal investigator 1 ModernaTX, Inc. $11,764.85 03/19/2025 Non-covered Recipient Entity
NOBLE CLINICAL RESEARCH LLC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252989898
Principal investigator 1 ModernaTX, Inc. $17,029.41 02/21/2025 Non-covered Recipient Entity
NOBLE CLINICAL RESEARCH LLC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252989910
Principal investigator 1 ModernaTX, Inc. $13,170.60 01/22/2025 Non-covered Recipient Entity
NOBLE CLINICAL RESEARCH LLC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252989902
Principal investigator 1 ModernaTX, Inc. $1,260.00 01/10/2025 Non-covered Recipient Entity
NOBLE CLINICAL RESEARCH LLC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252989890